Friday, May 1, 2026

THE KOREAN WAR IS OVER! Did Seoul Just Concede Defeat To North Korea By Offering MDL Talks?

South Korea proposes inter-Korean military talks to clarify the MDL, aiming to reduce tensions and prevent accidental clashes.

AI Overcomes Nature’s Challenges: Neutralizing Snake Venom with Protein Design

The 2024 Nobel Prize in Chemistry was awarded for AI-designed proteins that neutralize snake venom, revolutionizing drug development.

SBS Drama ‘The Fiery Priest 2’ Kicks Off with HYNN’s Thrilling New Track

K-pop singer HYNN (Park Hye Won) has been chosen as the first artist for the soundtrack of The Fiery Priest 2.

Tag: rare

Samsung’s G-CROWN Platform is Revolutionizing Gene Therapy for Rare Diseases in Asia

Samsung Medical Center launches G-CROWN platform to develop gene therapies for rare diseases, aiming to reduce reliance on imports.

YH35995: A Game-Changer for Gaucher Disease? FDA Grants Orphan Drug Designation

Yuhan Corp's YH35995 for Gaucher disease receives orphan drug designation, enhancing its development for rare diseases with unmet needs.

Unlocking Genetic Insights: Family Insight Test Launches for High-Risk Families in Asia

3billion launches the Family Insight Test, a genomic diagnostic tool for high-risk families, enhancing genetic risk assessment and family planning.

1 Trillion KRW Donation: How the Lee Kun-hee Legacy is Transforming Infectious Disease Research in Korea

Samsung's donation aids childhood cancer and rare diseases, funding research and infrastructure to combat infectious diseases in South Korea.

3Billion Partners with Austin: What This Means for Rare Disease Diagnostics in the U.S.

3Billion partners with Austin for a new lab to enhance rare disease diagnostics and expand its U.S. market presence.

Unlocking Rare Diseases: How AI and Whole Genome Sequencing Achieved 46.2% Diagnostic Success in Korea

Three Billion, an AI-based rare disease diagnostic company, collaborates with Seoul National University Hospital on a major genomic study.

Top News

- Our Sponsors Ad -

Follow us